23 Sep 2025
Oncology Division
Hetero Healthcare Ltd., one of India’s leading pharmaceutical companies, has launched Perzea, the most affordable biosimilar of Pertuzumab, in collaboration with Enzene Biosciences Ltd. This milestone strengthens Hetero’ s commitment to making advanced breast cancer therapies accessible and affordable across India.
Pertuzumab, a monoclonal antibody, is globally recognised as the standard of care in combination with trastuzumab and chemotherapy for HER2-positive breast cancer. With Perzea, Hetero Healthcare aims to bridge the treatment gap, reduce cost barriers, and improve patient outcomes nationwide.
Mr. M. Srinivas Reddy, Managing Director, Hetero Healthcare Ltd., said: “At Hetero Healthcare, our focus has always been on innovation and affordability. The launch of Perzea, in collaboration with Enzene Biosciences, highlights our commitment to bringing world-class cancer therapies within reach of Indian patients.”
